A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients With Malignant Solid Tumors
Latest Information Update: 09 Apr 2023
At a glance
- Drugs JCXH-211 (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Immorna
Most Recent Events
- 03 Apr 2023 Status changed from recruiting to active, no longer recruiting.
- 08 Nov 2022 Planned initiation date changed from 1 Sep 2022 to 1 Nov 2022.
- 08 Nov 2022 Status changed from not yet recruiting to recruiting.